Recent discussions on X about Hims & Hers Health (HIMS) have been ignited by the company's launch of a new menopause and perimenopause care platform, sparking a notable surge in stock price. Many users are expressing enthusiasm over the telehealth firm's innovative approach to addressing underserved markets in women's health, viewing it as a potential game-changer in the industry. The buzz reflects a sense of optimism about the company's ability to capitalize on emerging healthcare trends.
However, not all chatter is uniformly positive, as some voices on X raise concerns about potential regulatory scrutiny and competitive pressures in the telehealth space. There are also mentions of volatility in the stock's recent performance, with debates on whether the current price reflects long-term growth potential. This mix of excitement and caution paints a complex picture of investor sentiment surrounding HIMS.
Note: This discussion summary was generated from an AI condensation of post data.
Hims & Hers Health Congressional Stock Trading
Members of Congress have traded $HIMS stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN purchased up to $15,000 on 08/04.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Hims & Hers Health Insider Trading Activity
Hims & Hers Health insiders have traded $HIMS stock on the open market 91 times in the past 6 months. Of those trades, 0 have been purchases and 91 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:
- ANDREW DUDUM (Chief Executive Officer) has made 0 purchases and 41 sales selling 1,760,192 shares for an estimated $89,857,306.
- OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 12 sales selling 357,772 shares for an estimated $19,732,067.
- MICHAEL CHI (Chief Commercial Officer) has made 0 purchases and 13 sales selling 91,401 shares for an estimated $5,410,838.
- PATRICK HARRISON CARROLL (Chief Medical Officer) has made 0 purchases and 2 sales selling 70,021 shares for an estimated $3,720,938.
- MELISSA BAIRD (Chief Operating Officer) has made 0 purchases and 6 sales selling 66,666 shares for an estimated $2,726,632.
- SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 13 sales selling 38,497 shares for an estimated $2,005,534.
- IRENE BECKLUND (PAO) has made 0 purchases and 4 sales selling 24,902 shares for an estimated $1,280,807.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Hims & Hers Health Hedge Fund Activity
We have seen 316 institutional investors add shares of Hims & Hers Health stock to their portfolio, and 198 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL WORLD INVESTORS added 18,559,302 shares (+inf%) to their portfolio in Q2 2025, for an estimated $925,181,204
- D. E. SHAW & CO., INC. removed 4,143,604 shares (-68.7%) from their portfolio in Q2 2025, for an estimated $206,558,659
- INVESCO LTD. added 2,128,587 shares (+502.2%) to their portfolio in Q2 2025, for an estimated $106,110,061
- CONTRARIUS GROUP HOLDINGS LTD removed 1,749,968 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $87,235,904
- CLEAR STREET LLC added 1,676,667 shares (+inf%) to their portfolio in Q2 2025, for an estimated $83,581,849
- NORGES BANK added 1,574,009 shares (+inf%) to their portfolio in Q2 2025, for an estimated $78,464,348
- BANK OF MONTREAL /CAN/ added 1,515,809 shares (+5701.5%) to their portfolio in Q2 2025, for an estimated $75,563,078
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Hims & Hers Health Analyst Ratings
Wall Street analysts have issued reports on $HIMS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 2 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 09/12/2025
- Citigroup issued a "Sell" rating on 05/06/2025
- B of A Securities issued a "Underperform" rating on 04/29/2025
To track analyst ratings and price targets for Hims & Hers Health, check out Quiver Quantitative's $HIMS forecast page.
Hims & Hers Health Price Targets
Multiple analysts have issued price targets for $HIMS recently. We have seen 8 analysts offer price targets for $HIMS in the last 6 months, with a median target of $38.0.
Here are some recent targets:
- Maria Ripps from Canaccord Genuity set a target price of $68.0 on 09/12/2025
- Jailendra Singh from Truist Securities set a target price of $37.0 on 08/18/2025
- Craig Hettenbach from Morgan Stanley set a target price of $40.0 on 06/11/2025
- Ryan MacDonald from Needham set a target price of $65.0 on 06/04/2025
- Korinne Wolfmeyer from Piper Sandler set a target price of $39.0 on 05/06/2025
- Daniel Grosslight from Citigroup set a target price of $30.0 on 05/06/2025
- Allen Lutz from B of A Securities set a target price of $26.0 on 04/29/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
